How Much Weight Do You Lose on Wegovy in the First Month?

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

When you start Wegovy or any GLP-1 medication, your first month may feel like a slow beginning. Clinical data shows that most patients lose between 1 and 3 pounds in that initial four-week window, which is considerably less dramatic than the losses seen by month three or four. This measured start is intentional: your healthcare provider uses that time to monitor how your body tolerates semaglutide and gradually escalates your dose to maximize both safety and results.

Typical First Month Weight Loss on Semaglutide Injections

The STEP 1 trial, which examined once-weekly semaglutide in people with obesity, documented that participants lost an average of 1.5 to 3.0 pounds during the first four weeks of treatment. This initial phase occurs while you remain on the lowest maintenance dose—usually 0.25 mg—which allows your gastrointestinal system time to acclimate to the medication without overwhelming nausea or side effects. By the end of week four, most patients report reduced hunger and improved appetite control, even if the scale movement appears modest.

Individual results during month one vary based on starting weight, baseline metabolism, and how quickly your body responds to GLP-1 receptor activation. Someone beginning treatment at 250 pounds may observe slightly different weight loss than someone starting at 180 pounds, though the percentage change tends to be consistent. PlexusDx compounds semaglutide using the identical active pharmaceutical ingredient found in Wegovy, meaning your first-month experience on compounded therapy mirrors what clinical trials demonstrate.

Why Weight Loss Accelerates After the First Month

The true acceleration happens in weeks 5 through 12, when your dose advances from 0.25 mg to 0.5 mg, then often to 1.0 mg by the end of month three. Each dose increase triggers a deeper suppression of hunger hormones and delays stomach emptying, resulting in more sustained satiety throughout the day. Patients frequently report that their appetite control and food satisfaction shift dramatically once they reach therapeutic doses—precisely why month two and three losses typically exceed 5 to 7 pounds combined.

This staggered dosing strategy serves a clinical purpose: it minimizes gastrointestinal side effects, improves medication adherence, and allows your body's hunger-regulating pathways time to recalibrate. Rushing to higher doses in week one would likely cause severe nausea and dropout rates that contraindicate the entire treatment course. Your compounded semaglutide follows the same evidence-based titration schedule as brand-name Wegovy, ensuring both safety and optimal long-term results.

Factors That Influence Your First Month Outcome

Your genetics, starting body composition, and adherence to the injection schedule all shape how much you lose in the opening month. The PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R pathways to map how your body's peptide signaling responds to semaglutide therapy. Someone with specific GLP1R or GIPR variants may experience faster hunger suppression and earlier appetite control, translating to slightly steeper first-month losses, whereas other genetic profiles may require a longer adjustment window.

Diet quality, physical activity level, and sleep consistency during those first four weeks also predict individual outcomes. Patients who maintain a calorie deficit while taking their weekly injection see more reliable weight loss than those who continue previous eating patterns. Additionally, staying hydrated, managing stress, and getting adequate sleep support the metabolic and hormonal shifts that semaglutide initiates—all factors within your control that amplify medication effectiveness from day one.

Compounded vs. Brand-Name Semaglutide: First-Month Results

PlexusDx sources semaglutide from licensed 503A compounding pharmacies, which manufacture the medication to the same United States Pharmacopeia (USP) standards as brand products. Your first-month weight loss trajectory on compounded semaglutide is clinically equivalent to Wegovy because the active ingredient, injection technique, and dosing schedule remain identical. The primary difference is cost: PlexusDx charges $149 per month flat, regardless of dose tier, whereas Wegovy typically costs $900 to $1,350 monthly through traditional insurance or out-of-pocket channels.

Starting compounded semaglutide at PlexusDx means you receive the same week-by-week hunger suppression, gastrointestinal adjustment period, and modest first-month losses that Wegovy patients experience—but without insurance requirements, membership fees, or insurance copays. HSA and FSA funds cover your treatment, and no prior authorization delays your access. By month two, when your dose increases and weight loss accelerates, you'll benefit from the same evidence-based protocol as any Wegovy patient, at a fraction of the cost.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do most people lose in their first month on Wegovy or semaglutide?

Clinical trials show that most patients lose 1 to 3 pounds in the first month while on the starting 0.25 mg dose. This modest initial loss is expected and normal—your body is adapting to the medication while your appetite hormones begin to shift. Significant weight loss typically accelerates starting in month two as your dose increases to 0.5 mg and beyond.

Is 1–3 pounds per month considered good progress on semaglutide?

Yes. In the STEP trials, participants who started semaglutide lost an average of 15 to 22% of their baseline body weight over 68 weeks. That consistent, sustainable loss is far more effective for long-term weight management than rapid, unsustainable drops that often lead to regain. Month-one losses of 1–3 pounds set a solid foundation for the faster results you'll see in months 2–4.

How does PlexusDx compounded semaglutide compare to Wegovy for first-month weight loss?

PlexusDx compounded semaglutide produces identical first-month results because it contains the same active ingredient and follows the same dosing schedule. The key difference is price: PlexusDx starts at $149/month flat, covers all 50 states, requires no insurance, and is HSA/FSA eligible—delivering the same clinical outcomes at significantly lower cost.

Why is my first-month weight loss so slow compared to what I expected?

Your first month uses the lowest therapeutic dose (0.25 mg) to allow your body to adapt and minimize side effects. This measured approach prevents severe nausea and improves long-term adherence. Weight loss accelerates substantially once your dose increases to 0.5 mg and 1.0 mg in weeks 5–12. Expecting 1–3 pounds in month one is realistic and aligned with clinical evidence.

Can the PlexusDx Precision Peptide Genetic Test predict my first-month weight loss?

Yes. PlexusDx's genetic test analyzes GLP1R, GIPR, FTO, and MC4R variants across 14 pathways to reveal how your peptide signaling responds to semaglutide. Certain genetic profiles may show slightly faster initial appetite suppression, while others require more time for the medication's full effects to emerge. This insight helps your provider optimize your personalized dosing and set realistic first-month expectations.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.